目的：探讨司美格鲁肽联合二甲双胍对2型糖尿病合并周围神经病变（DPN）患者神经传导和炎症因子的影响。方法：选取64例DPN患者，分为研究组（n=32）和对照组（n=32）。对照组口服二甲双胍，研究组司美格鲁肽皮下注射联合口服二甲双胍。对比两组空腹血糖（FPG）、餐后2h血糖（2hPG）、糖化血红蛋白（HbA1c）、腓总神经运动神经传导速度（CPN-MCV）、腓总神经感觉神经传导速度（CPN-SCV）、正中神经运动神经传导速度（MN-MCV）、正中神经感觉神经传导速度（MN-SCV）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）及临床疗效。结果：治疗后，研究组FPG（7.47±1.16mmol/L vs. 8.20±1.22mmol/L）、2hPG（9.75±1.50mmol/L vs. 10.82±1.69mmol/L）及HbA1c（5.76±0.70% vs. 7.11±0.79%）较对照组降低（P＜0.05）。研究组CPN-MCV（51.18±4.02m/s vs. 48.01±4.56m/s）、CPN-SCV（46.69±4.40m/s vs. 43.51±4.66m/s）、MN-MCV（46.79±3.53m/s vs. 43.42±4.68m/s）及（41.97±4.08m/s vs. 38.56±3.50m/s）较对照组升高（P＜0.05）。研究组血清IL-6及TNF-α水平较对照组降低（P＜0.05）。 研究组有效率高于对照组（96.87% vs. 78.12%，P＜0.05）。结论：司美格鲁肽联合二甲双胍治疗DPN患者疗效确切，有助于改善神经传导功能，降低炎症因子表达。

目的 探讨不同剂量左甲状腺素钠联合二甲双胍治疗妊娠期糖尿病（GDM）并发甲状腺功能减退症（简称“甲减”）患者的临床疗效，并分析其对甲状腺激素水平、妊娠结局的影响。方法 选取2023年1月～2025年1月于本院诊治的92例GDM并发甲减患者为研究对象，依据治疗方案不同将其分为2组，对照组采用左甲状腺素钠、二甲双胍治疗，观察组采用维生素D联合左甲状腺素钠、二甲双胍治疗。比较2组临床疗效及治疗前后甲状腺激素[促甲状腺激素（TSH）、游离三碘甲状腺原氨酸（FT3）、游离甲状腺激素（FT4）]、糖脂代谢指标[空腹血糖、胰岛素抵抗指数（HOMA-IR）、总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）]、血管内皮功能[一氧化氮（NO）、内皮素-1（ET-1）、一氧化氮合酶（NOS）、非对称性二甲基精氨酸（ADMA）]、病情进展相关指标[成纤维细胞生长因子-21（FGF-21）、视黄醇结合蛋白4（RBP4）、脂蛋白相关磷脂酶A2（Lp-PLA2）]。比较2组妊娠结局。结果 观察组总有效率高于对照组（P＜0.05）；观察组治疗后TSH水平低于对照组，FT3、FT4水平高于对照组（P＜0.05）；观察组治疗后空腹血糖水平、TC、TG、LDL-C水平及HOMA-IR低于对照组（P＜0.05）；观察组治疗后NO、NOS水平高于对照组，ET-1、ADMA水平低于对照组（P＜0.05）；观察组治疗后血清FGF-21、RBP4、Lp-PLA2水平低于对照组（P＜0.05）；2组流产、胎盘早剥、新生儿窒息发生率比较无明显差异（P＞0.05），观察组早产发生率低于对照组（P＜0.05）。结论 维生素D联合左甲状腺素钠、二甲双胍治疗GDM并发甲减患者的效果显著，可更好地维持甲状腺功能正常，纠正糖脂代谢，改善血管内皮功能，控制疾病进展，并可在一定程度上改善妊娠结局。

目的 探究二甲双胍在多囊卵巢综合征(polycystic ovary syndrome,PCOS)患者中的促排卵效果。方法 选取2019年1月—2020年12月收治的66例PCOS患者进行回顾性分析,以治疗方案为依据进行分组(对照组、观察组),对照组均采用炔雌醇环丙孕酮进行治疗(n=33),观察组则在其基础上联合二甲双胍进行治疗(n=33),对比两组患者的性激素水平[黄体酮生成素(luteinizing hormone,LH)、睾酮(testosterone,T)]、血糖指标[空腹血糖(fasting plasma glucose,FPG)、空腹胰岛素(fasting insulin,FINS)、胰岛素抵抗指数]及促排卵效果。结果 观察组在治疗后的LH、T水平均低于对照组(P＜0.05);且观察组在治疗后的FPG、FINS、胰岛素抵抗指数水平均低于对照组(P＜0.05);此外,经过治疗后,观察组患者的排卵率为54.5%,高于对照组的30.3%(P＜0.05)。结论 将二甲双胍应用于PCOS患者的治疗方案中,可显著改善其性激素水平及血糖代谢情况,促进排卵率的提升,在PCOS导致的不孕症治疗中具有积极的应用价值。

Objective To explore the effect of metformin on ovulation induction in patients with polycystic ovarian syndrome (PCOS). Methods A total of 66 cases of PCOS patients from January 2019 to December 2020 were retrospectively analyzed and divided into control group and observation group according to the treatment plan. The control group was treated with ethinylestradiol and cyproterone (n=33), while the observation group was treated with metformin additionally (n=33). The levels of sex hormone (luteinizing hormone,testosterone),the indexes of fasting plasma glucose (FPG), fasting insulin (FINS) and homeostasis model assessment for insulin resistance (HOMA-IR) in the two groups were compared. The effects of ovulation induction were evaluated. Results The hormone levels of the observation group after treatment were lower than those of the control group (P<0.05); and the FPG, FINS and HOMA-IR levels of the observation group after treatment were lower than those of the control group (P<0.05); in addition,the ovulation rate of the observation group was 54.5% after treatment, which was higher than that of the control group (30.3%, P<0.05). Conclusion Metformin in the treatment of PCOS patients could greatly improve their sex hormone levels and blood glucose metabolism, promote ovulation rate, and has application value in the treatment of infertility caused by PCOS.

目的 本研究从细胞生物学角度检测二甲双胍对小鼠胰岛瘤MIN6的影响,并探讨此过程中包含的分子生物学机制。方法 MTT法检测不同浓度二甲双胍(1、2、5、10、20 mmol/L)对MIN6细胞活力的影响,细胞划痕实验检测二甲双胍对MIN6细胞迁移的影响,免疫印记实验检测此过程中细胞凋亡相关蛋白Bcl-2、Bax、caspase3表达的变化,及AMPK和JNK信号通路蛋白磷酸化水平的变化。结果 二甲双胍浓度大于10 mmol/L时可以抑制MIN6细胞的活力(P<0.01),降低其迁移能力(P<0.01),高浓度二甲双胍可以上调细胞内凋亡蛋白Bax(P<0.05)和p-AMPK的表达(P<0.05),降低抗凋亡蛋白Bcl-2的表达,增加caspase3剪切体(P<0.05)。同时,二甲双胍可以降低MIN6细胞内JNK信号通路的磷酸化水平(P<0.05)。结论 高浓度二甲双胍可以抑制MIN6细胞的增殖和迁移,其作用可能与降低了JNK信号的通路活化有关。

Objective This study aims to investigate the effect of metformin on proliferation and migration of MIN6 cells, and to explore the underlying mechanism. Methods The viability of MIN6 cells that were treated with various metformin (1,2,5,10 and 20 mmol/L) was detected by MTT assay. The migration of MIN6 cells was determined by wound-healing assay. Meanwhile, the proteins expression of Bcl-2, Bax, caspase3 and the phosphorylation of AMPK, JNK was detected by western bolt assay. Results The cell viability and the migration of MIN6 cells were decreased when the concentration of metformin above 10 mmol/L(P<0.01). The expression of apoptosis-related protein Bax(P<0.05) and p-AMPK(P<0.05)was up-regulated, anti-apoptosis-related protein Bcl-2 was down-regulated and cleaved caspase3 (P<0.05)was increased after high metformin treatment. At the same time, the phosphorylation of JNK was down-regulated by metformin(P<0.05). Conclusion High concertration of metformin may inhibit the proliferation and migration of MIN6 cells through suppressing the activation of JNK signaling pathway.

目的 探讨炔雌醇环丙孕酮联合二甲双胍对多囊卵巢综合征(PCOS)患者促排卵结局及性激素水平的影响。方法 选择2015年3月—2016年12月我院收治的多囊卵巢综合征(PCOS)患者90例,将其参照随机数字表法分为2组,各45例。对照组给予炔雌醇环丙孕酮治疗,在此基础上给予观察组二甲双胍治疗,1个疗程后评估两组临床疗效、性激素水平、药物不良反应,并观察治疗6个月后2组促排卵结局。结果 观察组治疗总有效率、排卵率、妊娠率均较对照组高,T、E₂、LH水平较对照组低,差异具有统计学意义(P＜0.05);观察组不良反应率与对照组相比,差异无统计学意义(P＞0.05)。结论 炔雌醇环丙孕酮联合二甲双胍可显著提高PCOS临床疗效,改善性激素水平及促排卵结局,且不增加不良反应率,安全性较高。

目的 探讨利拉鲁肽与二甲双胍对新诊断2型糖尿病患者骨代谢的影响。方法 选取2016年1月—2017年6月在我院就诊并确诊为新诊断2型糖尿病患者50例,按照随机数字表法将研究对象随机分为利拉鲁肽组及二甲双胍组,每组各25人。两组患者均单药治疗24周后比较两组患者骨密度、骨代谢指标变化情况。结果 两组患者骨密度、血清ALP以及BGP、PINP水平治疗前后相比,无改变(P>0.05);而利拉鲁肽组患者的β-CTx水平较治疗前降低(P<0.05);两组患者治疗后FPG、2hFPG、HOMA-IR、HbA1c均较治疗前下降(P<0.05),而空腹胰岛素较治疗前上升(P<0.05);利拉鲁肽组患者治疗24周后BMI值低于治疗前(P<0.05)。结论 利拉鲁肽与二甲双胍对新诊断2型糖尿病患者骨密度的影响均不明显,两种药物可有效降低血糖,改善胰岛素抵抗,利拉鲁肽在使用过程中可明显降低患者血清β-CTx水平,但其是否存在骨质保护作用仍需进一步研究。

Objective To explore the effect of liraglutide and metformin on bone metabolism in newly diagnosed type 2 diabetic patients. Methods From January 2016 to June 2017, 50 patients with type 2 diabetes mellitus admitted to our hospital were selected. According to the random number table method, the subjects were randomly divided into liraglutide group and metformin group, 25 in each group. Changes in bone mineral density and bone metabolism were compared between the two groups after 24 weeks of monotherapy. Results That there was no significant change in bone mineral density, serum ALP, TPINP,and BGP levels before and after treatment (P>0.05). The β-CTx levels in patients in the liraglutide group were lower than that before treatment (P<0.05); FPG, 2hFPG, HOMA-IR, and HbA1c levels in the two groups were lower than that before treatment (P<0.05). Fasting insulin was higher than that before treatment (P<0.05); BMI was lower in the liraglutide group after 24 weeks of treatment than that before treatment (P<0.05). Conclusion The effects of liraglutide and metformin on the bone mineral density of patients with newly diagnosed type 2 diabetes are not obvious. Liraglutide may reduce serum β-CTx levels during use. We need to have further study whether it has a bone protection.

目的 探讨二甲双胍和胰高糖素样多肽-1对2型糖尿病患者并发骨折恢复的影响。方法 选取2016年5月—2017年4月我院骨科收治的2型糖尿病并发骨折患者120例,按随机原则分为5组,每组24例,单药低剂量二甲双胍组(A1)、单药高剂量二甲双胍组(A2)、单药GLP-1组(B)、低剂量二甲双胍联合GLP-1组(C1)和高剂量二甲双胍联合GLP-1组(C2)。二甲双胍低剂量用药量为0.5 g/次,每日2次口服,高剂量用药量为0.5 g/次,每日4次口服。皮下注射利拉鲁肽每日1次,起始量为每日0.6 mg,1周增加为每日1.2 mg,再1周后增加为每日1.8 mg。血糖控制在理想水平后按照标准的手术方法和规程行相应的手术治疗。同时给予饮食控制及其它对症治疗。分别在1、3、6个月时检测其股骨颈骨密度值(BMD)和Harris系统评分。结果 随着治疗时间延长,A1组、C1组、C2组BMD值和Harris系统评分均增高, 在术后3月和6月时,C1组骨密度值和Harris评分高于A1组(P<0.05), C1组骨密度值和Harris评分高于C2组(P<0.05)。结论 胰高糖素样多肽-1可促进2型糖尿病患者骨折愈合、功能恢复,且与低剂量二甲双胍联用促进骨折愈合效果优于与高剂量二甲双胍联用。

Objective To investigate the effects of metformin and glucagon like polypeptide -1 on fracture recovery in patients with type 2 diabetes mellitus(DM). Methods We selected 120 patients with type 2 diabetes mellitus from May 2016 to April 2017 in department of orthopedicsin in our hospital and randomly divided them into 5 groups, 24 cases in each group,includingthe low dose of metformin monotherapy group (A1), the high dose of metformin monotherapy group (A2), single drug GLP-1 group (B), and GLP-1 group low dose of metformin combination (C1) and high dose of metformin combination with GLP-1 group (C2). The low dose of metformin was 0.5 g / time, 2 times a day for oral administration. The high dose was 0.5 g / time, 4 times a day. Subcutaneous injection of liraglutide was once daily, starting at a daily dose of 0.6 mg, 1.2 mg daily after 1 week and 1.8 mg daily after another week. After an ideal level of blood glucose control, corresponding surgical procedures should be performed according to standard surgical methods and procedures. Diet control and other symptomatic treatments were also given. The femoral neck bone mineral density (BMD) and the Harris system score were examined at the first, third, and sixth month respectively. Results With the prolongation of treatment time, the BMD value and Harris system score in the A1 group, C1 group, C2 group were increased. After surgery in March and June, the BMD and Harris score of C1 group were higher than that of A1 group (P<0.05). The bone mineral density and Harris score of C1 group was significantly higher than that of group C2 (P<0.05). Conclusion Glucagon like peptide -1 may promote the fracture recovery and functional recovery in patients with type 2 diabetes mellitus, and with combination of low dose metformin is more effective than that with high dose metformin.

目的 探讨DPP-4抑制剂联合二甲双胍治疗2型糖尿病的临床疗效及安全性。方法 选取医院近3年收治的糖尿病病人70例,随机分为对照组(35例)和治疗组(35例),对照组给予二甲双胍治疗,治疗组给予二甲双胍联合DPP-4抑制剂控制血糖,经3个月治疗,比较治疗后血糖指标、胰岛功能指标及低血糖、不良反应情况。结果 对照组和治疗组治疗后FPG、2hPG、HbA1c水平均有降低,治疗组治疗后血糖检测指标优于对照组(P＞0.05)。胰岛功能监测显示治疗组治疗后空腹胰岛素、服糖后2小时胰岛素浓度升高优于对照组,胰高血糖素水平降低幅度大于对照组,治疗前后胰岛素及胰高血糖素均有变化,组间比较P＞0.05,有临床意义。治疗期间两组患者均未发生低血糖、药物不良反应。结论 DPP-4抑制剂联合二甲双胍可显著提高降糖效果,改善胰岛功能,并且无低血糖、药物不良反应发生。